Protective effects of tanshinone IIA derivative on myocardial ischemia/reperfusion injury in rats

doi:10.5246/jcps.2018.01.001

Abstract

Abstract:

Tanshinone IIA (TSIIA) is the major bioactive constituent of Salvia miltiorrhiza Bunge, a Chinese herbal medicine, which has protective effects on myocardial ischemia/reperfusion (MIR) injury. However, the cardioprotective effects of TSIIA as well as its clinical use were limited due to its poor water solubility. The objective of this study was to evaluate whether Tanshinone IIA derivative (TD), a new water soluble compound synthesized by TSIIA and N-Methyl-D-Glucamine, had protective effects on MIR injury and what the related mechanism was. The cardioprotective effects of TD were evaluated and compared with TSIIA in a rat MIR model. The results show that pretreatment with TD significantly alleviated inflammatory infiltration and exhibited antioxidant effect in MIR injury by reducing the activity of lactate dehydrogenase (LDH) and malondialdehyde (MDA), decreasing expression of nuclear factor-κ-gene binding (NF-κB) and upregulating expression of heme oxygenase (HO-1), but having no effect on the content of total superoxide dismutase (T-SOD) and mRNA expression of superoxide dismutase (SOD-1). Thus, our study reveals that TD exerted significant protective effects on MIR injury through attenuating oxidative stress and inflammatory responses.

Key words: Myocardial ischemia/reperfusion, Tanshinone IIA derivative, Tanshinone IIA

CLC Number:

R962

Supporting:

Wanli Shen, Fei Yu, Lu Xu, Cong Chen, Yini Cao, Shu Liu, Nanyin Han, Chao Wang, Rong Qi. Protective effects of tanshinone IIA derivative on myocardial ischemia/reperfusion injury in rats[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(1): 1-13.

References

[1] Zhao, G.L.; Yu, L.M.; Gao, W.L.; Duan, W.X.; Jiang, B.; Liu, X.D.; Zhang, B.; Liu, Z.H.; Zhai, M.E.; Jin, Z.X.; Yu, S.Q.; Wang, Y. Berberine protects rat heart from ischemia/reperfusion injury via activating JAK2/STAT3 signaling and attenuating endoplasmic reticulum stress. Acta Pharmacol. Sin. 2016, 37, 354-367.

[2] Maxwell, S.R.; Lip, G.Y. Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Int. J. Cardiol. 1997, 58, 95-117.

[3] Park, J.L.; Lucchesi, B.R. Mechanisms of myocardial reperfusion injury. Ann Thorac. Surg. 1999, 68, 1905-1912.

[4] Murphy, E.; Steenbergen, C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol. Rev. 2008, 88, 581-609.

[5] Jordan, J.E.; Zhao, Z.Q.; Vinten-Johansen, J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res. 1999, 43, 860-878.

[6] Lam, F.F.; Yeung, J.H.; Cheung, J.H.; Or, P.M. Pharma-cological evidence for calcium channel inhibition by danshen (Salvia miltiorrhiza) on rat isolated femoral artery. J. Cardiovasc Pharmacol. 2006, 47, 139-145.

[7] Zhou, Y.; Li, W.; Xu, L.; Chen, L. In Salvia miltiorrhiza, phenolic acids possess protective properties against amyloid beta-induced cytotoxicity, and tanshinones act as acetylcholinesterase inhibitors. Environ. Toxicol. Pharmacol. 2011, 31, 443-452.

[8] Wong, K.K.; Ho, M.T.; Lin, H.Q.; Lau, K.F.; Rudd, J.A.; Chung, R.C.; Fung, K.P.; Shaw, P.C.; Wan, D.C. Cryptotanshinone, an acetylcholinesterase inhibitor from Salvia miltiorrhiza, ameliorates scopolamine-induced amnesia in Morris water maze task. Planta Med. 2010, 76, 228-34.

[9] Zhang, H.N.; An, C.N.; Zhang, H.N.; Pu, X.P. Protocatechuic acid inhibits neurotoxicity induced by MPTP in vivo. Neurosci Lett. 2010, 474, 99-103.

[10] Kang, D.G.; Oh, H.; Sohn, E.J.; Hur, T.Y.; Lee, K.C.; Kim, K J.; Kim, T.Y.; Lee, H.S. Lithospermic acid B isolated from Salvia miltiorrhiza ameliorates ischemia/reperfusion-induced renal injury in rats. Life Sci. 2004, 75, 1801-1816.

[11] Lin, Y.L.; Wu, C.H.; Luo, M.H.; Huang, Y.J.; Wang, C.N.; Shiao, M.S.; Huang, Y.T. In vitro protective effects of salvianolic acid B on primary hepatocytes and hepatic stellate cells. J. Ethnopharmacol. 2006, 105, 215-222.

[12] Wu, Z.M.; Wen, T.; Tan, Y.F.; Liu, Y.; Ren, F.; Wu, H. Effects of salvianolic acid a on oxidative stress and liver injury induced by carbon tetrachloride in rats. Basic Clin. Pharmacol. Toxicol. 2007, 100, 115-120.

[13] Zhang, H.S.; Wang, S.Q. Salvianolic acid B from Salvia miltiorrhiza inhibits tumor necrosis factor-alpha (TNF-alpha)-induced MMP-2 upregulation in human aortic smooth muscle cells via suppression of NAD(P)H oxidase-derived reactive oxygen species. J. Mol. Cell Cardiol. 2006, 41, 138-148.

[14] Tian X,X.W.; Ding X. Application of Danshen injection on early stage of renal transplantation. Chin. J. Integr. Med. 2005, 25, 404-407.

[15] O’Brien, K.A.; Ling, S.; Abbas, E.; Dai, A.; Zhang, J.; Wang, W.C.; Bensoussan, A.; Luo, R.; Guo, Z.X.; Komesaroff, P.A. A Chinese herbal preparation containing radix salviae miltiorrhizae, radix notoginseng and borneolum syntheticum reduces circulating adhesion molecules. Evid. Based Complement. Alternat. Med. 2011, 2011, 790784.

[16] Xu, W.; Yang, J.; Wu, L.M. Cardioprotective effects of tanshinone IIA on myocardial ischemia injury in rats. Pharmazie. 2009, 64, 332-336.

[17] Fu, J.; Huang, H.; Liu, J.; Pi, R.; Chen, J.; Liu, P. Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur. J. Pharmacol. 2007, 568, 213-221.

[18] Ren, Z.H.; Tong, Y.H.; Xu, W.; Ma, J.; Chen, Y. Tanshinone IIA attenuates inflammatory responses of rats with myocardial infarction by reducing MCP-1 expression. Phytomedicine. 2010, 17, 212-218.

[19] Tong, Y.; Xu, W.; Han, H.; Chen, Y.; Yang, J.; Qiao, H.; Hong, D.; Wu, Y.; Zhou, C. Tanshinone IIA increases recruitment of bone marrow mesenchymal stem cells to infarct region via up-regulating stromal cell-derived factor-1/CXC chemokine receptor 4 axis in a myocardial ischemia model. Phytomedicine. 2011, 18, 443-450.

[20] Jun Song, L.; Xin, X.; Liu Qing, D.; Li Hua, C. Design of self-micro emulsifying drug delivery systems for tanshione IIA. Chin. J. New Drugs. 2010, 21, 1980-1985.

[21] Chen, K. The therapeutic effect of purified coronary heart II tablets on 112 cases of angina pectoris by double blind method. Chin. J. Integr. Tradit. West. Med. 1982, 10, 85-89.

[22] Shi, Y. Comparative Study of composite Danshen droplet pills and sordi in treatment of patients with chronic stable angina. Chin. J. Integr. Tradit. West. Med. 1997, 17, 23-25.

[23] Wei, B.; You, M.G.; Ling, J.J.; Wei, L.L.; Wang, K.; Li, W.W.; Chen, T.; Du, Q.M.; Ji, H. Regulation of antioxidant system, lipids and fatty acid beta-oxidation contributes to the cardioprotective effect of sodium tanshinone IIA sulphonate in isoproterenol-induced myocardial infarction in rats. Atherosclerosis. 2013, 230, 148-156.

[24] Liu, H.C.; Liu, H.H. Adverse reactions of tanshinone II(A) sodium sulfonate injection in treating 18 cases: an analysis of clinical features. Chin. J. Integr. Tradit. West. Med. 2013, 33, 1287-1289.

[25] Chen, J.K.; Shen, C.R.; Liu, C.L. N-acetylglucosamine: production and applications. Mar. Drugs. 2010, 8, 2493-2516.

[26] Ren-an, Q.; Juan, L.; Chuyuan, L.; Wenjuan, F.; Chunyan, H.; Xuemei, Y.; Lin, H.; Hong, N. Study of the protective mechanisms of Compound Danshen Tablet (Fufang Danshen Pian) against myocardial ischemia/reperfusion injury via the Akt-eNOS signaling pathway in rats. J. Ethnopharmacol. 2014, 156, 190-198.

[27] Pan, Y.; Qian, J.X.; Lu, S.Q.; Chen, J.W.; Zhao, X.D.; Jiang, Y.; Wang, L.H.; Zhang, G.X. Protective effects of tanshinone IIA sodium sulfonate on ischemia-reperfusion-induced myocardial injury in rats. Iran. J. Basic Med. Sci. 2017, 20, 308-315.

[28] Myska, J. Vysoka Skola Chem-Technol Prague Sb Vysoke Skoly Chem-Technol Praze. Org. Technol. 1961, 5219-5233.

[29] Gao, S.; Liu, Z.; Li, H.; Little, P.J.; Liu, P.; Xu, S. Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis. 2012, 220, 3-10.

[30] Hausenloy, D.J.; Mocanu, M.M.; Yellon, D.M. Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc. Res. 2004, 63, 305-312.

[31] Hausenloy, D.J.; Yellon, D.M. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J. Clin. Invest. 2013, 123, 92-100.

[32] Gerczuk, P.Z.; Kloner, R.A. An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J. Am. Coll. Cardiol. 2012, 59, 969-978.

[33] Kitakaze, M.; Asakura, M.; Kim, J.; Shintani, Y.; Asanuma, H.; Hamasaki, T.; Seguchi, O.; Myoishi, M.; Minamino, T.; Ohara, T.; Nagai, Y.; Nanto, S.; Watanabe, K.; Fukuzawa, S.; Hirayama, A.; Nakamura, N.; Kimura, K.; Fujii, K.; Ishihara, M.; Saito, Y.; Tomoike, H.; Kitamura, S.; investigators, J. W. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007, 370,1483-1493.

[34] Li, G.R.; Wang, H.B.; Qin, G.W.; Jin, M.W.; Tang, Q.; Sun, H.Y.; Du, X.L.; Deng, X.L.; Zhang, X.H.; Chen, J.B.; Chen, L.; Xu, X.H.; Cheng, L.C.; Chiu, S.W.; Tse, H.F.; Vanhoutte, P.M.; Lau, C.P. Acacetin, a natural flavone, selectively inhibits human atrial repolarization potassium currents and prevents atrial fibrillation in dogs. Circulation. 2008, 117, 2449-2457.

[35] Sofija, J.; Aleksandar, J. Models of cardioprotection. Drug Discovery Today: Disease Models. 2007, 4, 185-190.

[36] Kabay, S.; Ozden, H.; Guven, G.; Burukoglu, D.; Ustuner, M.C.; Topal, F.; Gunes, H.V.; Ustuner, D.; Ozbayer, C. Protective effects of the nuclear factor kappa B inhibitor pyrrolidine dithiocarbamate on experimental testicular torsion and detorsion injury. Korean J. Physiol. Pharmacol. 2014, 18, 321-326.

[37] Frank, A.; Bonney, M.; Bonney, S.; Weitzel, L.; Koeppen, M.; Eckle, T. Myocardial ischemia reperfusion injury: from basic science to clinical bedside. Semin Cardiothorac Vasc. Anesth. 2012, 16 , 123-132.

[38] Liu, H.; Yang, L.; Wu, H.J.; Chen, K.H.; Lin, F.; Li, G.; Sun, H.Y.; Xiao, G.S.; Wang, Y.; Li, G.R. Water-soluble acacetin prodrug confers significant cardioprotection against ischemia/reperfusion injury. Sci. Rep. 2016, 6, 36435.

[39] Heusch, G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res. 2015, 116, 674-699.

[40] Skyschally, A.; Gent, S.; Amanakis, G.; Schulte, C.; Kleinbongard, P.; Heusch, G. Across-Species Transfer of Protection by Remote Ischemic Preconditioning With Species-Specific Myocardial Signal Transduction by Reperfusion Injury Salvage Kinase and Survival Activating Factor Enhancement Pathways. Circ. Res. 2015, 117, 279-288.

[41] Liao, Y.F.; Zhu, W.; Li, D.P.; Zhu, X. Heme oxygenase-1 and gut ischemia/reperfusion injury: A short review. World J. Gastroenterol. 2013, 19, 3555-3561.

[42] An, L.; Liu, C.T.; Yu, M.J.; Chen, Z.H.; Guo, X.G.; Peng, W.; Wang, J.F.; Fang, X.Q.; Gao, Y.H.; Yu, S.Y. Heme oxygenase-1 system, inflammation and ventilator-induced lung injury. Eur. J. Pharmacol. 2012, 677, 1-4.

[43] Paine, A.; Eiz-Vesper, B.; Blasczyk, R.; Immenschuh, S. Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem. Pharmacol. 2010, 80, 1895-1903.

[44] Aztatzi-Santillan, E.; Nares-Lopez, F.E.; Marquez-Valadez, B.; Aguilera, P.; Chanez-Cardenas, M.E. The protective role of heme oxygenase-1 in cerebral ischemia. Cent. Nerv. Syst. Agents Med. Chem. 2010, 10, 310-316.

[45] Ryter, S.W.; Choi, A.M. Heme oxygenase-1/carbon monoxide: novel therapeutic strategies in critical care medicine. Curr. Drug Targets. 2010, 11, 1485-1494.

[46] Yeh, C.H.; Chen, T.P.; Wang, Y.C.; Lin, Y.M.; Lin, P.J. HO-1 activation can attenuate cardiomyocytic apoptosis via inhibition of NF-kappaB and AP-1 translocation following cardiac global ischemia and reperfusion. J. Surg. Res. 2009, 155, 147-156.